CPNG Coupang, Inc.


$ 27.65 $ -0.03 (-0.11 %)    

Tuesday, 18-Nov-2025 12:38:33 EST
QQQ $ 596.76 $ -2.88 (-0.48 %)
DIA $ 461.07 $ -1.15 (-0.25 %)
SPY $ 660.29 $ -1.84 (-0.28 %)
TLT $ 88.89 $ -0.46 (-0.51 %)
GLD $ 374.53 $ -0.31 (-0.08 %)
$ na
$ 27.64
$ 27.61 x 578
$ 27.61 x 400
$ 27.39 - $ 27.83
$ 19.02 - $ 34.08
9,440,490
na
50.8B
nm
$ 130.25
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-coupang-raises-price-target-to-40

Barclays analyst Jiong Shao maintains Coupang (NYSE:CPNG) with a Overweight and raises the price target from $36 to $40.

 mizuho-maintains-neutral-on-coupang-raises-price-target-to-32

Mizuho analyst James Lee maintains Coupang (NYSE:CPNG) with a Neutral and raises the price target from $30 to $32.

 stocks-rebound-eli-lilly-jumps-to-14-month-highs-whats-moving-markets-wednesday

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...

 b-of-a-securities-maintains-buy-on-coupang-raises-price-target-to-38

B of A Securities analyst Susie Lee maintains Coupang (NYSE:CPNG) with a Buy and raises the price target from $36 to $38.

 palantir-weighs-on-wall-street-bitcoin-slumps-5-whats-moving-markets-tuesday

Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...

 arete-research-initiates-coverage-on-coupang-with-buy-rating-announces-price-target-of-40

Arete Research analyst Richard Kramer initiates coverage on Coupang (NYSE:CPNG) with a Buy rating and announces Price Target...

 us-judge-dismisses-shareholder-lawsuit-against-e-commerce-company-coupang-over-ipo

-Reuters Citing Court Documents

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION